Re: Jarow JP et al.: Clinical Trial Design For the Development of New Therapies for Non–muscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop (Urology 2014;83:262-265)

Muscle Invasive ◽

American Urological Association

Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop

Urology ◽

10.1016/j.urology.2013.10.030 ◽

2014 ◽

Vol 83 (2) ◽

pp. 262-265 ◽

Cited By ~ 37

Author(s):

Jonathan P. Jarow ◽

Seth P. Lerner ◽

Paul G. Kluetz ◽

Ke Liu ◽

Rajeshwari Sridhara ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Drug Administration ◽

Trial Design ◽

Food And Drug Administration ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

New Therapies ◽

American Urological Association ◽

Nonmuscle Invasive Bladder Cancer

Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

Nature Reviews Urology ◽

10.1038/s41585-021-00505-w ◽

2021 ◽

Author(s):

Elaine Chang ◽

Andrea B. Apolo ◽

Rick Bangs ◽

Stephanie Chisolm ◽

Vinay Duddalwar ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Neoadjuvant Therapy ◽

Drug Administration ◽

Trial Design ◽

Clinical Trial Design ◽

Advocacy Network ◽

Muscle Invasive ◽

Therapy Clinical Trial

Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design

The Journal of Urology ◽

10.1097/ju.0000000000001633 ◽

2021 ◽

Author(s):

Justin T. Matulay ◽

Roger Li ◽

Patrick J. Hensley ◽

Nathan A. Brooks ◽

Vikram M. Narayan ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Bcg Therapy ◽

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer

European Urology ◽

10.1016/j.eururo.2021.12.005 ◽

2021 ◽

Author(s):

Mathieu Roumiguié ◽

Ashish M. Kamat ◽

Trinity J. Bivalacqua ◽

Seth P. Lerner ◽

Wassim Kassouf ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Consensus Statement ◽

Clinical Trial Design ◽

Bacillus Calmette Guerin ◽

Group Consensus ◽

Cancer Group ◽

Faculty Opinions recommendation of Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739122585.793581022 ◽

2020 ◽

Author(s):

Otto Hemminki

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

The effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of non-muscle invasive bladder cancer. Preliminary results of the PRECAVE prospective, controlled, randomized clinical trial

European Urology ◽

10.1016/s0302-2838(21)01132-5 ◽

2021 ◽

Vol 79 ◽

pp. S1043-S1044

Author(s):

D.M. Carrión Monsalve ◽

J. Gomez Rivas ◽

C.R. Trelles ◽

C. Ballesteros Ruiz ◽

M. Alvarez-Maestro ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Randomized Clinical Trial ◽

Invasive Bladder Cancer ◽

Preliminary Results ◽

Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2021.11.001 ◽

2021 ◽

Author(s):

Giovanni Cochetti ◽

Jacopo Adolfo Rossi de Vermandois ◽

Vincenza Maulà ◽

Luigi Cari ◽

Rosy Cagnani ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

High Risk ◽

Diagnostic Performance ◽

Invasive Bladder Cancer ◽

Photodynamic Diagnosis ◽

Single Centre ◽

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Reply.

The Journal of Urology ◽

10.1097/ju.0000000000002238 ◽

2021 ◽

Author(s):

Patrick J. Hensley ◽

Ashish M. Kamat

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Trial Design ◽

Clinical Trial Design ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Nonmuscle Invasive Bladder Cancer

The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the PRECAVE randomized clinical trial.

10.37554/en-j.arch.esp.urol-20210704-3511-30 ◽

2021 ◽

Author(s):

Diego Carrión ◽

Juan Gómez Rivas ◽

Cristina Ballesteros Ruiz ◽

Mario Álvarez-Maestro ◽

Emilio Ríos González ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Randomized Clinical Trial ◽

Interim Analysis ◽

Invasive Bladder Cancer ◽

Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial

European Urology Focus ◽

10.1016/j.euf.2018.02.005 ◽

2019 ◽

Vol 5 (5) ◽

pp. 849-852

Author(s):

Peter F.A. Mulders ◽

Luis Martínez-Piñeiro ◽

Axel Heidenreich ◽

Marko Babjuk ◽

Marc Colombel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Lessons Learned ◽

Invasive Bladder Cancer ◽

Phase 2 ◽